Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma
- PMID: 32999219
- PMCID: PMC7946499
- DOI: 10.2169/internalmedicine.4241-19
Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma
Abstract
Drug-induced immune hemolytic anemia (DIIHA) is a rare condition with an increasing incidence associated with the frequent use of certain drugs. An 85-year-old woman with lung adenocarcinoma prescribed alectinib complained of dyspnea on exertion at our hospital. Based on her laboratory tests results on admission, we focused on the clinical course of anemia and hemolysis progression after alectinib administration. The patient's anemia and hemolysis gradually improved after discontinuation of alectinib, leading to a diagnosis of alectinib-induced IHA, presented here as the first case encountered in a patient with lung adenocarcinoma. Furthermore, we discuss the importance of correlating clinical laboratory findings in DIIHA.
Keywords: alectinib; anaplastic lymphoma kinase; coombs-negative autoimmune hemolytic anemia; drug-induced immune hemolytic anemia; lung cancer.
Conflict of interest statement
Figures




Similar articles
-
Alectinib-induced Hemolytic Anemia with Positive Direct Antiglobulin Test in a Patient with Lung Adenocarcinoma: A Possible Drug-drug Interaction Effect.Intern Med. 2024 Mar 1;63(5):711-715. doi: 10.2169/internalmedicine.1286-22. Epub 2023 Jul 12. Intern Med. 2024. PMID: 37438141 Free PMC article.
-
Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.Invest New Drugs. 2015 Oct;33(5):1148-50. doi: 10.1007/s10637-015-0284-9. Epub 2015 Sep 4. Invest New Drugs. 2015. PMID: 26334220
-
Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.Lung Cancer. 2016 Sep;99:66-8. doi: 10.1016/j.lungcan.2016.06.017. Epub 2016 Jun 23. Lung Cancer. 2016. PMID: 27565916
-
Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature.J Med Case Rep. 2018 Oct 19;12(1):303. doi: 10.1186/s13256-018-1849-y. J Med Case Rep. 2018. PMID: 30336782 Free PMC article. Review.
-
Hemolytic Anemia With Acanthocytes During Alectinib Treatment of Anaplastic T-Cell Lymphoma: A Case Report and Literature Review.J Pediatr Hematol Oncol. 2025 Apr 1;47(3):123-126. doi: 10.1097/MPH.0000000000003003. Epub 2025 Feb 17. J Pediatr Hematol Oncol. 2025. PMID: 39961014 Review.
Cited by
-
Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report.Onco Targets Ther. 2023 Jan 24;16:65-69. doi: 10.2147/OTT.S398375. eCollection 2023. Onco Targets Ther. 2023. PMID: 36718244 Free PMC article.
-
Piperacillin-tazobactam induced immune hemolytic anemia led to increased renal impairment and eventual death from multiple organ failure in a patient with hypertensive nephropathy: case report and literature review.BMC Nephrol. 2023 Jun 14;24(1):173. doi: 10.1186/s12882-023-03235-w. BMC Nephrol. 2023. PMID: 37316798 Free PMC article. Review.
-
Alectinib-induced Hemolytic Anemia with Positive Direct Antiglobulin Test in a Patient with Lung Adenocarcinoma: A Possible Drug-drug Interaction Effect.Intern Med. 2024 Mar 1;63(5):711-715. doi: 10.2169/internalmedicine.1286-22. Epub 2023 Jul 12. Intern Med. 2024. PMID: 37438141 Free PMC article.
-
Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report.Front Pharmacol. 2025 May 21;16:1545614. doi: 10.3389/fphar.2025.1545614. eCollection 2025. Front Pharmacol. 2025. PMID: 40469976 Free PMC article.
References
-
- Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev 24: 143-150, 2010. - PubMed
-
- Chapman AM, Sun KY, Ruestow P, Cowan DM, Madl AK. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. Lung Cancer 102: 122-134, 2016. - PubMed
-
- Thai AA, Solomon BJ. Treatment of ALK-positive nonsmall cell lung cancer: recent advances. Curr Opin Oncol 30: 84-91, 2018. - PubMed
-
- Open-label randomized PhaseIII Study of the Efficacy and Safety of CH5424802(AF802) in ALK-Positive Advanced or Recurrent Non-Small Cell Lung Cancer with Crizotinib control [Internet]. [cited 2019 Nov 19]. Available from: http://image.packageinsert.jp/pdf.php?mode=1&yjcode=4291032M1029
-
- Dhaliwal G, Cornett PA, Tierney LM Jr. Hemolytic anemia. Am Fam Physician 69: 2599-2606, 2004. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical